Treatment of the mouse model of mucopolysaccharidosis I with retrovirally transduced bone marrow

Yi Zheng, Nora Rozengurt, Sergey Ryazantsev, Donald B. Kohn, Noriko Satake, Elizabeth F. Neufeld

Research output: Contribution to journalArticle

58 Citations (Scopus)

Abstract

Mucopolysaccharidosis I is a lysosomal storage disorder caused by mutations in the IDUA gene, resulting in deficiency of α-L-iduronidase and accumulation of glycosaminoglycans. Bone marrow transplantation has been the only available therapy, soon to be joined by enzyme replacement. We have tested retroviral gene therapy in a knockout mouse model of the disease. Bone marrow from Idua-/- male donor mice was transduced with human IDUA cDNA in an MND vector and transplanted into 6-8-week-old, lethally irradiated female Idua-/- mice. Sham-treated mice received Idua-/- bone marrow that was either unmodified or transduced with eGFP. Unmodified Idua+/+ (wild type) bone marrow was transplanted for comparison. Recipient mice were sacrificed 2-6 months after transplantation. Three biochemical parameters were used to gauge therapeutic success: appearance of α-L-iduronidase activity, reduction of β-hexosaminidase activity and reduction of soluble glycosaminoglycan accumulation. Transplantation of unmodified +/+ bone marrow was effective in reducing storage in liver and spleen, but not in kidney or brain. The level of α-L-iduronidase activity achieved by transplantation of IDUA-transduced bone marrow varied greatly between experiments. But even modest activity resulted in correction of pathology of kidney, bladder epithelium, fibrocartilage, choroid plexus, and thalamus, as seen by light microscopy, while electron microscopy showed the presence of some normal neurons in the cortex. The partial correction of brain pathology is attributed to migration of donor hematopoietic cells, demonstrated by the presence of the Y chromosome and of normal microglia in the brain of mice receiving IDUA cDNA.

Original languageEnglish (US)
Pages (from-to)233-244
Number of pages12
JournalMolecular Genetics and Metabolism
Volume79
Issue number4
DOIs
StatePublished - Aug 1 2003
Externally publishedYes

Fingerprint

Mucopolysaccharidosis I
Iduronidase
Bone
Bone Marrow
Brain
Glycosaminoglycans
Bone Marrow Transplantation
Pathology
Complementary DNA
Transplantation
Fibrocartilage
Kidney
Therapeutics
Thermodynamic properties
Hexosaminidases
Choroid Plexus
Y Chromosome
Microglia
Gene therapy
Thalamus

Keywords

  • α-L-Iduronidase
  • Bone marrow transplantation
  • Gene therapy
  • Glycosaminoglycan
  • Hurler
  • Lysosome
  • Mouse model
  • Mucopolysaccharidosis
  • Retroviral vector

ASJC Scopus subject areas

  • Biochemistry
  • Genetics
  • Endocrinology, Diabetes and Metabolism

Cite this

Treatment of the mouse model of mucopolysaccharidosis I with retrovirally transduced bone marrow. / Zheng, Yi; Rozengurt, Nora; Ryazantsev, Sergey; Kohn, Donald B.; Satake, Noriko; Neufeld, Elizabeth F.

In: Molecular Genetics and Metabolism, Vol. 79, No. 4, 01.08.2003, p. 233-244.

Research output: Contribution to journalArticle

Zheng, Yi ; Rozengurt, Nora ; Ryazantsev, Sergey ; Kohn, Donald B. ; Satake, Noriko ; Neufeld, Elizabeth F. / Treatment of the mouse model of mucopolysaccharidosis I with retrovirally transduced bone marrow. In: Molecular Genetics and Metabolism. 2003 ; Vol. 79, No. 4. pp. 233-244.
@article{78cb2f0101a24b0cba80e505cd404e28,
title = "Treatment of the mouse model of mucopolysaccharidosis I with retrovirally transduced bone marrow",
abstract = "Mucopolysaccharidosis I is a lysosomal storage disorder caused by mutations in the IDUA gene, resulting in deficiency of α-L-iduronidase and accumulation of glycosaminoglycans. Bone marrow transplantation has been the only available therapy, soon to be joined by enzyme replacement. We have tested retroviral gene therapy in a knockout mouse model of the disease. Bone marrow from Idua-/- male donor mice was transduced with human IDUA cDNA in an MND vector and transplanted into 6-8-week-old, lethally irradiated female Idua-/- mice. Sham-treated mice received Idua-/- bone marrow that was either unmodified or transduced with eGFP. Unmodified Idua+/+ (wild type) bone marrow was transplanted for comparison. Recipient mice were sacrificed 2-6 months after transplantation. Three biochemical parameters were used to gauge therapeutic success: appearance of α-L-iduronidase activity, reduction of β-hexosaminidase activity and reduction of soluble glycosaminoglycan accumulation. Transplantation of unmodified +/+ bone marrow was effective in reducing storage in liver and spleen, but not in kidney or brain. The level of α-L-iduronidase activity achieved by transplantation of IDUA-transduced bone marrow varied greatly between experiments. But even modest activity resulted in correction of pathology of kidney, bladder epithelium, fibrocartilage, choroid plexus, and thalamus, as seen by light microscopy, while electron microscopy showed the presence of some normal neurons in the cortex. The partial correction of brain pathology is attributed to migration of donor hematopoietic cells, demonstrated by the presence of the Y chromosome and of normal microglia in the brain of mice receiving IDUA cDNA.",
keywords = "α-L-Iduronidase, Bone marrow transplantation, Gene therapy, Glycosaminoglycan, Hurler, Lysosome, Mouse model, Mucopolysaccharidosis, Retroviral vector",
author = "Yi Zheng and Nora Rozengurt and Sergey Ryazantsev and Kohn, {Donald B.} and Noriko Satake and Neufeld, {Elizabeth F.}",
year = "2003",
month = "8",
day = "1",
doi = "10.1016/S1096-7192(03)00116-1",
language = "English (US)",
volume = "79",
pages = "233--244",
journal = "Molecular Genetics and Metabolism",
issn = "1096-7192",
publisher = "Academic Press Inc.",
number = "4",

}

TY - JOUR

T1 - Treatment of the mouse model of mucopolysaccharidosis I with retrovirally transduced bone marrow

AU - Zheng, Yi

AU - Rozengurt, Nora

AU - Ryazantsev, Sergey

AU - Kohn, Donald B.

AU - Satake, Noriko

AU - Neufeld, Elizabeth F.

PY - 2003/8/1

Y1 - 2003/8/1

N2 - Mucopolysaccharidosis I is a lysosomal storage disorder caused by mutations in the IDUA gene, resulting in deficiency of α-L-iduronidase and accumulation of glycosaminoglycans. Bone marrow transplantation has been the only available therapy, soon to be joined by enzyme replacement. We have tested retroviral gene therapy in a knockout mouse model of the disease. Bone marrow from Idua-/- male donor mice was transduced with human IDUA cDNA in an MND vector and transplanted into 6-8-week-old, lethally irradiated female Idua-/- mice. Sham-treated mice received Idua-/- bone marrow that was either unmodified or transduced with eGFP. Unmodified Idua+/+ (wild type) bone marrow was transplanted for comparison. Recipient mice were sacrificed 2-6 months after transplantation. Three biochemical parameters were used to gauge therapeutic success: appearance of α-L-iduronidase activity, reduction of β-hexosaminidase activity and reduction of soluble glycosaminoglycan accumulation. Transplantation of unmodified +/+ bone marrow was effective in reducing storage in liver and spleen, but not in kidney or brain. The level of α-L-iduronidase activity achieved by transplantation of IDUA-transduced bone marrow varied greatly between experiments. But even modest activity resulted in correction of pathology of kidney, bladder epithelium, fibrocartilage, choroid plexus, and thalamus, as seen by light microscopy, while electron microscopy showed the presence of some normal neurons in the cortex. The partial correction of brain pathology is attributed to migration of donor hematopoietic cells, demonstrated by the presence of the Y chromosome and of normal microglia in the brain of mice receiving IDUA cDNA.

AB - Mucopolysaccharidosis I is a lysosomal storage disorder caused by mutations in the IDUA gene, resulting in deficiency of α-L-iduronidase and accumulation of glycosaminoglycans. Bone marrow transplantation has been the only available therapy, soon to be joined by enzyme replacement. We have tested retroviral gene therapy in a knockout mouse model of the disease. Bone marrow from Idua-/- male donor mice was transduced with human IDUA cDNA in an MND vector and transplanted into 6-8-week-old, lethally irradiated female Idua-/- mice. Sham-treated mice received Idua-/- bone marrow that was either unmodified or transduced with eGFP. Unmodified Idua+/+ (wild type) bone marrow was transplanted for comparison. Recipient mice were sacrificed 2-6 months after transplantation. Three biochemical parameters were used to gauge therapeutic success: appearance of α-L-iduronidase activity, reduction of β-hexosaminidase activity and reduction of soluble glycosaminoglycan accumulation. Transplantation of unmodified +/+ bone marrow was effective in reducing storage in liver and spleen, but not in kidney or brain. The level of α-L-iduronidase activity achieved by transplantation of IDUA-transduced bone marrow varied greatly between experiments. But even modest activity resulted in correction of pathology of kidney, bladder epithelium, fibrocartilage, choroid plexus, and thalamus, as seen by light microscopy, while electron microscopy showed the presence of some normal neurons in the cortex. The partial correction of brain pathology is attributed to migration of donor hematopoietic cells, demonstrated by the presence of the Y chromosome and of normal microglia in the brain of mice receiving IDUA cDNA.

KW - α-L-Iduronidase

KW - Bone marrow transplantation

KW - Gene therapy

KW - Glycosaminoglycan

KW - Hurler

KW - Lysosome

KW - Mouse model

KW - Mucopolysaccharidosis

KW - Retroviral vector

UR - http://www.scopus.com/inward/record.url?scp=0041387505&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0041387505&partnerID=8YFLogxK

U2 - 10.1016/S1096-7192(03)00116-1

DO - 10.1016/S1096-7192(03)00116-1

M3 - Article

C2 - 12948739

AN - SCOPUS:0041387505

VL - 79

SP - 233

EP - 244

JO - Molecular Genetics and Metabolism

JF - Molecular Genetics and Metabolism

SN - 1096-7192

IS - 4

ER -